AYTU BIOPHARMA, INC 8-K

What Happened Aytu BioPharma, Inc. (AYTU) filed an 8-K (Item 2.02) on May 13, 2026 announcing its fiscal 2026 third-quarter operational and financial results and issuing a related press release (furnished as Exhibit 99.1). The company scheduled a conference call and live audio webcast for May 13, 2026 at 4:30 p.m. Eastern to discuss the results and answer questions. The press release and call-access instructions are available on the company’s website.

Key Details

• Filing date: May 13, 2026 (Form 8-K, Item 2.02).
• Event: Conference call and live webcast on May 13, 2026 at 4:30 p.m. ET; available live and for replay via webcast and telephone.
• Press release: Furnished as Exhibit 99.1 to the 8-K.
• Legal note: The press release is furnished (not “filed”) and therefore is not subject to Section 18 liability nor automatically incorporated by reference into other SEC filings.

Why It Matters This 8-K signals that the company has released its latest quarterly operational and financial results and is holding a same-day earnings call where management will provide details and take questions — the primary forum for investors to hear management’s commentary on revenue, earnings, guidance, and business trends. Retail investors should review the press release and consider listening to the webcast or replay to assess performance metrics and any updates on strategy or operational changes.